Document:

EXHIBIT 10.6

 Exhibit 10.6 
  
 CONFIDENTIAL MATERIALS HAVE BEEN OMITTED FROM THIS EXHIBIT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. 
  
 SETTLEMENT AGREEMENT RELATING TO 
 ADVERTISING INVENTORY UNDER NAMING RIGHTS AGREEMENT 
 AND CONDITIONALLY MODIFYING SUITE LICENSE AGREEMENT 
  
 THIS SETTLEMENT AGREEMENT (this “Agreement”) is made and entered into as of the Effective Date (as hereafter defined) by and between SAVVIS
Communications Corporation (“SAVVIS”) and Kiel Center Partners, L.P. (“KCP” with each of KCP and SAVVIS being a “Party” and collectively being the “Parties”). 
  
 Whereas, SAVVIS and KCP are parties to that certain Arena Naming Rights
Agreement dated August 17, 2000, as amended (the “NRA”); 
  
 Whereas, the Parties are parties to that certain SAVVIS Center Suite License Agreement dated June 22, 2001, as amended (the “SLA”); 
  
 [**] 
  
 [**] 
  
 Whereas, the Parties desire to amicably resolve these disputes and further the good working relationship of the Parties; 
  
 Now Therefore, for mutual consideration, the sufficiency of which is hereby
acknowledged, the Parties hereby agree as of this 30th day of July 2003 (the “Effective Date”) as follows:

  

	 	1.	The Recitals above are incorporated into this Agreement by reference as if fully stated herein. All capitalized terms not defined in this Agreement shall have the meanings ascribed
to such terms in the NRA or SLA, as the case may be. 

  

	 	2.	KCP will include the Arena Graphic Logo on all ticket fronts going forward as required by the NRA, at its own cost and expense. 

  

	 	3.	KCP promptly will propose to SAVVIS designs incorporating the Arena Mark for the signage to be installed in the main lobby of the Arena with the understanding that the parties shall
meet as soon as commercially practicable thereafter to work in good faith to mutually approve the final design. Subject to a mutually agreeable design having been adopted by the Parties, KCP shall cause such approved signage to be placed in the main
lobby of the Arena as soon as commercially practicable, at its own cost and expense. The Parties further 

  
 [**] CONFIDENTIAL TREATMENT REQUESTED 
  

	 	 	1

	 	 
acknowledge that it is their mutual intention to have such signage in place prior to the commencement of the 2003-2004 St. Louis Blues hockey season.

  

	 	4.	KCP will undertake and use commercially reasonable efforts to obtain from the appropriate governmental authorities a variance that would allow the Arena Mark to be placed on the
roof of the Arena. [**] If such variance is obtained, KCP shall cause the Arena Mark to be placed on the Arena roof as soon as commercially practicable thereafter. Such actions shall be at KCP’s own cost and expense. SAVVIS agrees to cooperate
with KCP in its efforts to obtain the variance, provided, however, that such cooperation does not create on the part of SAVVIS any liability for the delivery or non-delivery of the Arena Mark on the Arena roof, or associated costs.

  

	 	5.	[**] 

  

	 	6.	In consideration of the mutual promises set forth herein, KCP grants SAVVIS a credit in the amount of [**] against the $1,250,000 payment obligation of SAVVIS due on or before
December 31, 2003 under the NRA. 

  

	 	7.	[**] 

  

	 	8.	For, and in consideration of the commitments made herein by the Parties, each Party and its officers, directors, shareholders, employees, agents, representatives, affiliates,
partners, parents, subsidiaries, heirs, successors and assigns do hereby completely release and forever discharge the other Party and all of its officers, directors, shareholders, agents, representatives, insurers, employees, affiliates, parents,
subsidiaries, successors and assigns from any and all claims, rights, demands, actions, liabilities, obligations, causes of action of any and all kinds, nature and character whatsoever, known or unknown, whether based on a tort, including, but not
limited to, a negligent or intentional tort, contract (implied, oral or written), statute or any other theory of recovery under any international, federal or state law and whether for damages (either compensatory, exemplary or aggravated) or
equitable relief, which the releasing Party has or may have, arising from or forming the basis of the matters set forth herein. 

  

	 	9.	The Parties shall keep all terms and the fact of this Agreement strictly confidential and shall not disclose the nature, terms, or negotiation of this Agreement to any third party
without prior written consent of the other, save as may be required by compulsion of law, provided, however, that in the event of any court order, witness summons or other direction of court, or duly authorized administrative agency or official to
provide such information, wherever possible the Party required to supply the information shall notify the other at least five (5) business days prior to the requested time for compliance; and further provided, that nothing in this paragraph shall
prevent a Party hereto from disclosing, without notice to the other Party, the nature, terms, or effect of this Agreement, to the Party’s affiliated entities (or their officers, directors, principals or partners), legal

  
 [**] CONFIDENTIAL TREATMENT
REQUESTED 
  

	 	 	2

	 	 
advisors, accountants, auditors, tax advisors, or, prospective investors in connection with funding efforts, or to the extent which may be necessary to
review and complete appropriate financial statements, so long as such persons are informed of, and agree to be bound by, this Paragraph, prior to disclosure of any such information to them. The Parties further acknowledge that SAVVIS may be required
to file this Agreement in connection with its SEC filings; if so required, SAVVIS will endeavor to seek confidential treatment to the extent permitted under applicable regulations. 

  

	 	10.	This Agreement has been executed by Parties for the sole purpose of settling certain disputes between them. It is expressly understood and agreed by the Parties that nothing
contained in this Agreement shall constitute, or be construed to be, an admission of liability, or evidence of the truthfulness of any allegations concerning the conduct of the Parties. 

  

	 	11.	All negotiations relating to this Agreement are merged herein. There are no promises, agreements, conditions, undertakings, warranties, or representations, oral or written, express
or implied, among the undersigned Parties as to such matters other than as set forth herein. No waiver, change or modification of this Agreement shall be valid unless the same is in writing and is signed by all of the Parties hereto.

  

	 	12.	The Parties represent that they have read this Settlement Agreement and Release, that they have consulted with counsel of their choice, and that they are fully aware of its contents
and of its legal effect. 

  

	 	13.	This Agreement shall be binding on each Party, and their respective successors and assigns. 

  

	 	14.	As modified hereby, the NRA and SLA remain in full force and effect. 

  

	 	15.	If any part of any provision of this Agreement shall be finally determined to be invalid or unenforceable under applicable law by a court of competent jurisdiction, that part shall
be ineffective to the extent of such invalidity or unenforceability only, without in any way affecting the remaining parts of said provision or the remaining provisions of this Agreement. 

  

	 	16.	This Agreement may be executed in any number of counterparts, with signature to each being deemed signature to all such counterparts, each of which shall be deemed to be an original
and all of which together shall constitute a single instrument. Facsimile signatures by the Parties shall be deemed accepted as if they are originals; provided, however, that the Parties deliver to each other originals of such facsimile signatures
promptly, but, in any event, within three (3) business days, following their execution of this Agreement. 

  
 [**] CONFIDENTIAL TREATMENT REQUESTED 
  

	 	 	3

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the Effective Date. 
  

	Kiel Center Partners, L.P.
		
	By:	 	/s/ Mark Sauer
	 Title:
	 	 President and CEO

  

	SAVVIS Communications Corporation
		
	By:	 	/s/ Lane H. Blumenfeld
	 Title:
	 	 Deputy General Counsel, Vice President
 & Assistant Secretary

  
 [**]
CONFIDENTIAL TREATMENT REQUESTED 
  

	 	 	4letterofintent Ex-10.1

LETTER OF INTENT 

BETWEEN: 

SKINVISIBLE PHARMACEUTICALS, INC. 

a Nevada company ("SKV") 

-and- 

Health First Distributors North America, Inc . 

British Columbia company ("Health First DNA") 

RE:  Acquisition of exclusive marketing rights to the antimicrobial hand sanitizer product identified as   

                                the Triclosan 1% formula manufactured by SKV, (the "Product") 

1.    Product: 

The product supplied by SKV to Health First DNA is an antimicrobial hand sanitizer product. This Letter of Intent deals only with this specific product and not to any other products manufactured by SKV now or in the future. 

 

 

2.    Rights : 

The rights to be granted involve the exclusive marketing and distribution rights to this Product, for North America, consisting of the countries of the United States of America, Canada and Mexico (the "Territory"). SKV agrees that it will transfer and assign to Health First DNA any marketing contracts involving the Product within the Territory, if any, upon completion of a formal Licensing Agreement and payment as required and subject to certain terms and conditions, as identified herein. 

SKV also agrees to provide to Health First DNA, the research studies on the Product and its efficacy referred to in SKV’s existing marketing CD on the Product exclusively to Health First DNA as they relate to the Product. Subject to completion of a formal agreement and payment as described above, within the Territory these studies will only be provided to Health First DNA. 

 

                  Health First DNA shall have the right of first refusal, subject to the completion of the North American marketing agreement to 

                  market products proprietary to Skinvisible using the Skinvisible trade name in any territory except for the rights already 

                  granted in the territories of S. Korea, China, Singapore, Hong Kong and Macao. 

 

                 Health First DNA shall be given 30 days from receipt of notice by Skinvisible that an offer to purchase certain

                 territory/territories has been made and to accept the new territory under the same terms as offered by the new party. 

	 	1 	 
	

3.   Price/Payment : 

        ($1,000,000) USD payable as follows: 

(a)     upon completion and signing of this Letter of Intent, Health First DNA agrees to pay to SKV a non-refundable deposit of 

          $100,000 USD; this non-refundable deposit is to paid no later than the close of business on July 31, 2003, in order for the 

          parties to continue towards an agreement; and 

 

      (b)     the balance of $900,000.00 USD shall be payable on or before October 31, 2003. On or before August 31, 2003 the 

                parties shall agree upon the terms of a formal License Agreement; 

 

    In the event that payments are not made as set out or a mutual satisfactory formal agreement entered into within the time period 

    set out, other than due to the fault of SKV, then SKV may, at its sole option terminate negotiations and retain, without claim or 

    demand from Health First DNA, any deposits paid. 

 

4.    Royalty : 

In addition to the payments set out above Health First DNA agrees to pay SKV a royalty equal to five (5.0%) percent of Gross Revenues received by Health First DNA in relation to the Product, whether directly or indirectly, during the term of any agreement. The royalty shall be calculated and paid quarterly. Health First DNA shall supply SKV with such documentation, including receipts and invoices as shall be reasonably necessary to allow SKV to confirm the accuracy of the royalty payment made. SKV shall have the right to audit the royalty payments and Health First DNA shall pay the cost of the audit only if results indicate that payments are less than 90% of what they should have been. Quarterly payments must be made no later than 30 days after the end of each quarter during the term of the agreement. 

 

5.    Performance: 

In order to maintain this agreement and the exclusivity granted herein, during the term of the agreement, Health First DNA must make quarterly payments that amount to at least $5,000 USD during the first quarter, at least $10,000 USD during the second quarter, $15,000 USD during the third quarter, at least $20,000 USD during the fourth quarter and at least $25,000 USD each quarter thereafter, whether by royalty or otherwise (top up payment). In the event of failure to make the quarterly payments, in full, and on time, SKV shall have the option either to (1) terminate the agreement upon notice; or (2) terminate the exclusivity of the agreement in which case the minimum quarterly royalty payment amount will also cease. Quarterly payments will not be cumulative. 

          

          6.    Conditions : 

           Health First DNA – acknowledges that it has used the Product for 3 months and is content with its efficacy and quality. 

           Subject to review of same, Health First DNA agrees to accept an assignment of other marketing contracts relating to the 

           Product already in existence. 

 

 

	 	2 	 
	

 

7.     Patents: 

SKV represents and warrants that it holds a US patent for the Product, and that it will provide it to Health First DNA for review. In addition, SKV advises that it has applied for Patent protection for the Product to the World International Property Organization for inclusive within the territory. 

8.      Warranty : 

SKV agrees that it will continue to manufacture the Product for Health First DNA according to the quality standards presently in place and as stated in the present Certificate of Analysis relating to the Product. SKV may assign its manufacturing obligations to third parties who shall be bound by the same standards. The parties shall mutually agree to terms as to minimum order quantities, packaging and other details in relation to order and delivery of the Product. 

9.      Arbitration : 

Any disagreements shall be referred to arbitration under the rules of the American Arbitration Association. If required the arbitration shall be dealt with by a sole arbitrator at Las Vegas, Nevada. 

10.     Non-competition : 

During the term of the agreement, Health First DNA agrees not to sell, market or be involved with any other product competitive to the Product, without the prior written consent of SKV. 

11.     Assignment : 

Health First DNA shall not be entitled to sell, transfer or assign its rights hereunder without the consent of SKV. 

12.     Investigation : 

Any information and documentation delivered by either party to the other shall will be treated as confidential except to the extent that (i) it was already known to that party or its representatives or available to that party on a non-confidential basis when received, (ii) it hereafter becomes lawfully obtainable from other sources; or (iii) it is disclosed by a party or its Principals in any document filed with any government agency or authority and available for public inspection. 

13.     No Brokers : 

The parties acknowledge and agree that they will each be responsible for any fees or expenses of any broker retained by them or on their behalf. 

 14.      Expenses: 

Each party shall bear its own costs and expenses (including all legal, accounting, investment banking and other costs) with respect to this transaction, whether the transaction is consummated or not, and the Agreement shall so provide. 

 

 

	 	3 	 
	

 

 

15.     Exclusivity : 

Unless negotiations between Health First DNA and SKV are terminated (it being understood that SKV will not unilaterally terminate negotiations prior to August 31, 2003 as long as Health First DNA is proceeding expeditiously and in good faith), SKV agrees not to solicit, negotiate, act upon or entertain in any way an offer from any other person or entity to acquire any rights in or to the Product for the Territory without notice to Health First DNA of such inquiry or interest. 

16.     Confidentiality : 

Except as required by law or as the parties agree in connection with ongoing due diligence, this Letter will be kept strictly confidential, and neither party, nor its affiliates, shall disclose Health First DNA’s interest in the potential acquisition, or any of the terms and conditions thereof. To the extent that disclosure becomes legally required, Health First DNA or SKV, as the case may be, shall be notified promptly before the required disclosure is made. 

17.      Non-Enforceability Termination : 

Except for the obligations of Health First DNA for the payments set out herein, neither this Letter of Intent nor any past or future conduct of the parties hereto, their affiliates, agents or representatives (other than the execution and delivery of the definitive exclusive License Agreement) shall be deemed to constitute a binding or enforceable agreement. Without limiting the generality of the foregoing, Health First DNA and SKV each agree on behalf of themselves and their affiliates not to institute or maintain any claims or proceedings which seek to establish, or which are otherwise based upon an assertion, that any such contractual relationship exists, except pursuant to the definitive Licensing Agreement if finalized, negotiated, executed and delivered by the parties. 

If the terms and conditions set forth above are acceptable to you, please so indicate by signing one copy of this letter below and returning it to the undersigned. 

 

Skinvisible Pharmaceuticals, Inc .                                                            Agreed & Accepted 

 

/s/ Terry Howlett                                                                                             July 9/ 03

____________________________________________ Date: _______________________________________________

 

 

Health First Distributors North America, Inc .                                         Agreed & Accepted 

 

/s/ Lynda Vallon                                                                                             July 9/ 03

 ____________________________________________Date:   __________________________________________                                                                                         

	 	4 	 
	

 

 

Addendum 

	
US Patent 

	
PCT Patent Application 

	
Product Price List 

	
Certificate of Analysis 

	
US Monograph – email 

	
Canada Monograph –email 

	
Canada DIN 

	
Distribution Agreement – Crosbie Kennedy Nasmark 

	
Approved Canada Label 

	 	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00057-of-00352.parquet"}]]